iSTAR Medical’s MINIject shows consistent results at 18-month follow-up in first-in-human trial (STAR-I)

- 10/07/2019

Wavre, Belgium: 10 July 2019 – iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIjectTM device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year.

The STAR-I trial demonstrated that the implantation of MINIject resulted in a mean pressure of 15.0 mmHg at 18-months, consistent with results reported at 1 year, and at a level expected to reduce the progression of glaucoma. In addition, almost two-thirds of the patients were able to stop taking their eye drops. These results confirm that the safety and effectiveness of MINIject is sustained over time, with minimal patient-management required.

More info on iSTAR Medical’s website.